4th Asia-Pacifi c Abstracts A531 (78.8%), retinopathy (27.9%) and nephropathy (22.2%); Indian were highest in PVD (26.8%), and CAD (34.4%); Chinese highest in stroke (12.1%). After adjusting for age, gender and ethnicity, the odds of having "optimal" glycemic control was higher for T2DM patients with nephropathy (Adj OR:1.50; 95% CI [1.19-1.89]) and stroke (Adj OR:1.51; 95% CI [1.17-1.96]) compared to PVD (Adj OR: 0.61; 95% CI [0.51-0.74]) and retinopathy (Adj OR: 0.65; 95% CI [0.53-0.79]). CONCLUSIONS: There were ethnic differences in the prevalence of diabetes-related complications. T2DM patients with stroke or nephropathy were more likely to achieve "optimal" HbA1c level than those with PVD or eye complications.
1
Novo Nordisk A/S, Copenhagen, Denmark; 2 Novo Nordisk, Søborg, Denmark; 3 Novo Nordisk, Bagsvaerd, Denmark; 4 University of Lyon, Lyon, France OBJECTIVES: Health technology Assessment (HTA) has a long history in Australia and NZ and is rapidly evolving in Asian countries. The aim of this research was to identify and review English written reports on diabetes among HTA agencies in Asia and Oceania. METHODS: ISPORs directory (http://www.ispor.org) listing worldwide HTA organizations were searched for agencies in Asia and Oceania with a valid link to a webpage were included. On each agencies webpage a search was done using the search term "diabetes" and English written assessments were included for further review. RESULTS: The following HTA agencies were searched: PBAC, MSAC ASERNIP-S, AHTA, CCE, CHERE, HTA, NIPH, CRECON, MAPI, PHIC, PKEBM, ICTACH, HSAC, NZHTA, HIRA, CDE and HITAP. Of those, only 14 relevant reports were found from Australia, NZ and Thailand. Two were found from PBAC, fi ve from AHTA, one from HSAC, two from NZHTA, and four from HITAP. The two reports from PBAC were describing how to improve National management of diabetes. The reports from AHTA were horizon scanning reports covering glucose monitoring, screening of gestational diabetes and detecting retinopathy. HSAC had a report on insulin pump whereas as NZHTA had one on glucose monitoring and one about clinical features detecting insulin resistance. The reports found on HITAP were in the form of published articles assessing cost effectiveness of two different antihypertensive therapies in diabetes, one assessing cost effectiveness of diabetes management and fi nally one assessing diabetes self management. Reports from HSAC, NZHTA and HITAP contained economic modeling with QALY as outcome. CONCLUSIONS: Despite of broad search criteria only 14 English written reports were found on diabetes. A headline in English on each assessment would facilitate information sharing and make it easier to evaluate the need for translational support.
PDB28 THE EFFECT OF METFORMIN BRAND SHIFT BY HOSPITAL ON ANTIDIABETICS UTILIZATION
Chen HY 1 , Chang HR 1 , Lang HC 2 1 Mackay Memorial Hospital, Taipei, Taiwan; 2 National Yang-Ming University, Taipei, Taiwan OBJECTIVES: Due to the effect of National Health Insurance drug price cut policy, the studied hospital has changed the manufactures of metformin four times in 5 years since July, 2004. The purpose of this study is to investigate the effects of the change in hospital drug brands on patients' utilization and the factors that infl uence patients' persistence on the use of metformin. METHODS: Data were sourced from a medical center in Taipei city during [2004] [2005] [2006] [2007] [2008] . We collected all the oral antidiabetic drugs used during the study period and classifi ed them into fi ve categories: Biguanid, Sulfonylures, α-glucosidase inhibitor, Thiazolidinediones, and Meglitinide. The quantity of all the antidiabetics used was transformed by using WHO/ATC into DDDs. In this study, Metformin was treated as the experimental group and all other antidiabetics drugs were the control groups. RESULTS: The results showed that the quantity of metformin prescribed was increasing during the study period in spite of the brand change. However, other categories of oral antidiabetes were also increasing due to the increase in number of patients. The percentage of all types of drug stayed relatively steadily, in which metformin itself occupied 21-23%, all Sulfonylureas drugs occupied 59-60%, α-glucosidase inhibitor occupied 3-4%, Thiazolidinediones occupied 10-11%, and Meglitinide occupied 4-5% during the study period. In addition, the results of logistic regressions showed that female patients with hypertension or hyperlipemia between the ages of 40~80 who live in Taipei city performed better persistence of seeking medical service. CONCLUSIONS: The results shows changing the brand of metformin did not decrease drug consumption and patient numbers. By analyzing the acceptance of generic drugs of patients and doctors, this study provides important information for hospital administrators and health administrators.
PDB29 STATUS AND TREATMENT OF TYPE 2 DIABETES IN CHINA
Vlachopioti Z 1 , Smith HT 1 , Colclough H 2 1 Eli Lilly & Co, Windlesham, Surrey, UK, 2 Adelphi, Macclesfi eld, Cheshire, UK OBJECTIVES: To explore current disease status and approach to care for patients with type 2 diabetes (T2DM) in China. METHODS: The study was performed using data from the Adelphi T2DM Disease Specifi c Programme (DSP©), a cross-sectional study of consulting patients providing insights into "real-world" behaviors and attitudes in clinical practice in 2008. The DSP collected data on 1648 patients with T2DM receiving at least one oral anti-diabetic with or without insulin and from 200 physicians (140 specialists and 60 internal medicine) across general hospitals in nine Chinese cities through physician interviews, patient record forms and patient- : 2.31%) and 29.67% were on dual OAD therapy (commonly Met + SU: 11.71%, Met + AGI: 4.37%, SU + AGI: 3.82%, Met + PGR: 4.25%, Met + TZD: 1.52%), while 28.09% of patients were on OAD + insulin therapy. Lack of gastrointestinal, liver function side effects and hypoglycemia risk, QD dosage, and benefi cial effects on blood pressure were the fi ve most cited unmet needs in non-insulin diabetes treatment highlighted by physicians. Mean (SD) patient-reported QoL (EQ-5D VAS) was 0.86 (0.18) and mean (SD) diabetes treatment satisfaction was 25.97(5.14)/36 where 0 is very dissatisfi ed and 36 very satisfi ed. CONCLUSIONS:
The study population of Chinese T2DM patients is relatively young and recently diagnosed. More than half were poorly controlled and the need for further therapeutic actions to improve glycemic control as well as better doctor/patient communication regarding treatment goals is clear.
PDB30 GLYCEMIC CONTROL IS WORSE AND COMPLICATIONS MORE PREVALENT IN TYPE 2 DIABETES PATIENTS WITH A HIGHER BMI IN CHINA
Smith HT 1 , Vlachopioti Z 1 , Colclough H 2 1 Eli Lilly & Co, Windlesham, Surrey, UK; 2 Adelphi, Macclesfi eld, Cheshire, UK OBJECTIVES: Examine BMI and achievement of diabetes treatment targets in patients with Type 2 Diabetes (T2DM). METHODS: The study used the 2008 Adelphi T2DM Disease Specifi c Programme© a cross-sectional study of consulting patients providing insights into 'real-world' behaviors and attitudes in clinical practice. Data was collected on 1648 patients with T2DM receiving at least one oral anti-diabetic with/ without insulin and 140 specialists and 60 internal medicine physicians distributed across general hospitals in nine Chinese cities through physician interviews, patient record forms and self-completed questionnaires. RESULTS: Across the 1648 patients in the study; mean (SD) age was 57.7 (12.6) years, 46% were ≤2 years from diagnosis and mean (SD) BMI was 24.0 (3.4) kg/m 2 . Nine percent of patients were obese (BMI ≥ 28 kg/m 2 ), 39% overweight (24 ≤ BMI < 28 kg/m 2 ) and 51% normal/underweight (BMI < 24 kg/m 2 ). Prevalence of comorbidities in this population was high; 49% reporting hypertension and 42% dyslipidemia (25% patients reported both). Glycemic control appeared worse in patients with a higher BMI. Twenty-two percent of patients with a BMI ≥ 28 had an HbA1c ≥ 9% and 39% had an HbA1c ≥ 8% compared to 10% of patients with a BMI between 19-27.9 having an HbA1c ≥ 9% and 22% having an HbA1c ≥ 8%. Only 35% of patients were aware of having an HbA1c target set by their physician. Comorbid conditions were more prevalent in overweight and obese patients. Among normal weight patients 31% reported no comorbid conditions compared to 22% of overweight patients and 17% of obese patients. Prevalence of hypertension, dyslipidemia and other macrovascular conditions were 44%, 36%, and 18% respectively among normal weight patients; 53%, 48%, and 19% among overweight patients and 65%, 55%, and 24% among obese patients. CONCLUSIONS:
The results indicate that obese patients report higher HbA1c and higher rates of complications compared to the normal weight patients and strategies to improve target better outcomes could include managing obesity.
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PGI2 A SYSTEMATIC REVIEW AND META-ANALYSIS OF LITERATURE ASSESSING CLINICAL EFFICACY OF TREATMENTS FOR PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B
Tantai N 1 , Chaikledkaew U 2 , Werayingyong P 3 , Teerawattananon Y 3 1 Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; 2 Division of Social and Administrative Pharmacy, Bangkok, Thailand; 3 Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand OBJECTIVES: An objective of this review was to assess clinical effi cacy in terms of "HBeAg seroconversion" of treatment options for HBeAg-positive chronic hepatitis B (CHB). METHODS: A systematic review of randomized controlled trials (RCTs) of treatments for patients with HBeAg-positive CHB was performed through the Medline and Cochrane databases. The clinical studies were included only if they assessed the effi cacy among the following treatment options namely 1) lamivudine; 2) entecavir; 3) interferon; and 4) interferon plus lamivudine. Indirect or mixed-treatment comparison meta-analysis with random effect model was employed to combine results of several studies. The meta-analysis was carried out using the WinBUGS14 software. Odds ratio (OR) and its 95% confi dence interval (CI) were presented. Heterogeneity test was applied for testing the variation of study outcomes between studies. RESULTS: There were 115 abstracts reviewed with eight relevant RCTs included in the analysis. None of eight RCTs included all four treatment options. Five studies compared HBeAg seroconversion between entecavir and lamivudine. There were three different studies comparing interferon with interferon plus lamivudine, interferon plus lamivudine with lamivudine, and interferon and interferon plus lamivudine with lamivudine. Indirect
